Central Asia Lumeichun Biotechnology Inc.
OOTC:ZYLMD0.80
USD
+0.62
(+342.73%)
ISIN
US8888472094
CUSIP
888847209
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Stephen W. Carnes
- Sector
- Consumer services
- Industry
- Movies/Entertainment
- Address
- Winter Park United States
- Website
- toccalife.com
- Similar Companies
- Business
- Central Asia Lumeichun Biotechnology Inc. is a biotechnology and life sciences enterprise engaged in the research, development, cultivation, processing, and commercialization of botanical extracts, functional health foods, dietary supplements, and agricultural bio-solutions. The company operates primarily across two core business segments: Health & Nutrition Products and Agricultural Biotechnology. Its product and service portfolio includes: functional botanical beverages and liquid herbal tonics formulated through microbial fermentation and fruit extraction; dietary supplements, nutritional powders, and wellness capsules designed for digestive health, metabolic support, and immune enhancement; high-purity botanical raw ingredients, including concentrated polyphenols, plant flavonoids, and organic extracts for food, beverage, and nutraceutical applications; contract manufacturing, custom formulation, and original equipment manufacturing (OEM) and original design manufacturing (ODM) extraction services for third-party wellness brands; and agricultural biotechnology solutions, including bio-organic fertilizers, microbial soil conditioners, and ecological plant nutrition agents engineered to improve soil health and crop resilience. Central Asia Lumeichun Biotechnology Inc. serves individual consumers, retail health chains, commercial agricultural producers, and institutional healthcare clients across Mainland China and Central Asian regional markets. In recent corporate and operational developments, the company completed a major strategic restructuring and corporate name change from Zhongyu Limei Bio-Technology Inc. to Central Asia Lumeichun Biotechnology Inc., reflecting a strategic pivot toward cross-border trade expansion across Central Asian markets under regional economic corridor initiatives. As part of this corporate reorganization, the company restructured its equity capital base under the OTC ticker symbol ZYLMD, formed cross-border distribution alliances with regional agricultural and consumer health distributors, upgraded its bio-fermentation and precision extraction manufacturing facilities to comply with international export standards, and launched a new line of functional herbal health drinks and microbial soil enhancement formulas. Founded in 2014 and incorporated in Nevada, Central Asia Lumeichun Biotechnology Inc. maintains its executive and operational headquarters in Xi'an, Shaanxi Province, China, operating through regional operating subsidiaries and production centers.